SpringWorks Therapeutics
SWTX
SWTX was delisted on the 30th of June, 2025.
209 hedge funds and large institutions have $2.91B invested in SpringWorks Therapeutics in 2024 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 95 increasing their positions, 55 reducing their positions, and 37 closing their positions.
73% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 55
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
1.93% less ownership
Funds ownership: 106.09% → 104.16% (-1.9%)
4% less funds holding
Funds holding: 217 → 209 (-8)
16% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 37
25% less capital invested
Capital invested by funds: $3.85B → $2.91B (-$945M)
86% less call options, than puts
Call options by funds: $1.59M | Put options by funds: $11.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DFO
Duquesne Family Office
New York
|
+$43M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
+$29.1M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$27.4M |
| 4 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$24.2M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$20.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$73.3M |
| 2 |
DM
Deerfield Management
New York
|
-$63.2M |
| 3 |
Millennium Management
New York
|
-$29.1M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$26.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$25.8M |
SWTX Hedge Fund Activity: Q2 2024 in Review
209 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q2 2024, worth a combined $2.91B — down 25% from $3.85B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of SWTX and 31 opened new positions — a net loss of 6 holders — while 55 trimmed existing stakes and 95 added.
The largest buyer was Duquesne Family Office, opening a new position worth an estimated $43M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $73.3M sold.
- 209 institutional investors held SpringWorks Therapeutics (SWTX) as of Q2 2024, down from 217 in Q1 2024.
- Funds reported $2.91B of SpringWorks Therapeutics stock for Q2 2024, down 25% quarter-over-quarter.
- 31 funds opened new SpringWorks Therapeutics positions in Q2 2024 and 37 closed out, a net change of -6 holders.
- The largest SpringWorks Therapeutics buyer in Q2 2024 was Duquesne Family Office, an estimated $43M added.
- The largest SpringWorks Therapeutics seller in Q2 2024 was Point72 Asset Management, an estimated $73.3M sold.
Based on aggregated 13F filings for Q2 2024.